MINERVA SURGICAL, INC.

MINERVA SURGICAL, INC. (UTRS)

$0.23

-0.02

(-8.87%)

Market is closed - opens 7 PM, 30 May 2023

Insights on MINERVA SURGICAL, INC.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 37.70M → 12.53M (in $), with an average decrease of 66.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -22.78M → -13.44M (in $), with an average increase of 69.5% per quarter

  • Vs TXG

    In the last 1 year, Minerva Surgical Inc has experienced a drawdown of -90.8%, however 10x Genomics Inc - Class A resisted the overall trend and outperformed by 90.3%

Performance

  • $0.22
    $0.25
    $0.23
    downward going graph

    4.74%

    Downside

    Day's Volatility :10.57%

    Upside

    6.12%

    downward going graph
  • $0.15
    $3.02
    $0.23
    downward going graph

    34.83%

    Downside

    52 Weeks Volatility :95.04%

    Upside

    92.38%

    downward going graph

Returns

PeriodMINERVA SURGICAL, INC.Sector (Health Care)Index (Russel 2000)
3 Months
-22.74%
0.3%
-6.7%
6 Months
23.99%
-6.1%
-3.7%
1 Year
-90.38%
-4.8%
-6.3%
3 Years
-97.44%
23.8%
26.9%

Highlights

Market Capitalization
44.6M
Book Value
$0.19
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.93
Wall Street Target Price
1.0
Profit Margin
-66.54%
Operating Margin TTM
-76.8%
Return On Assets TTM
-26.83%
Return On Equity TTM
-100.36%
Revenue TTM
51.9M
Revenue Per Share TTM
1.13
Quarterly Revenue Growth YOY
14.6%
Gross Profit TTM
27.2M
EBITDA
-29.2M
Diluted Eps TTM
-0.93
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.37
EPS Estimate Next Year
-0.31
EPS Estimate Current Quarter
-0.11
EPS Estimate Next Quarter
-0.09

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for MINERVA SURGICAL, INC.(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
1
Hold
1
1
2
Sell
00
00
4

Analyst Forecast

What analysts predicted

Upside of 334.78%

Current $0.23
Target $1.00

Company Financials

FY19Y/Y Change
Revenue
26.0M
-
Net Income
-52.0M
-
Net Profit Margin
-200.08%
-
FY20Y/Y Change
Revenue
37.8M
↑ 45.19%
Net Income
-18.3M
↓ 64.91%
Net Profit Margin
-48.36%
↑ 151.72%
FY21Y/Y Change
Revenue
52.1M
↑ 37.96%
Net Income
-21.5M
↑ 17.53%
Net Profit Margin
-41.2%
↑ 7.16%
FY22Y/Y Change
Revenue
50.3M
↓ 3.47%
Net Income
-34.1M
↑ 58.93%
Net Profit Margin
-67.83%
↓ 26.63%
Q4 FY21Q/Q Change
Revenue
13.6M
↑ 9.11%
Net Income
10.8M
↓ 435.13%
Net Profit Margin
79.21%
↑ 105.0%
Q1 FY22Q/Q Change
Revenue
10.9M
↓ 19.86%
Net Income
-10.9M
↓ 201.08%
Net Profit Margin
-99.91%
↓ 179.12%
Q2 FY22Q/Q Change
Revenue
13.0M
↑ 18.58%
Net Income
-5.6M
↓ 48.62%
Net Profit Margin
-43.29%
↑ 56.62%
Q3 FY22Q/Q Change
Revenue
12.6M
↓ 2.92%
Net Income
-11.3M
↑ 101.84%
Net Profit Margin
-90.0%
↓ 46.71%
Q4 FY22Q/Q Change
Revenue
37.7M
↑ 199.54%
Net Income
-22.8M
↑ 101.1%
Net Profit Margin
-60.42%
↑ 29.58%
Q1 FY23Q/Q Change
Revenue
12.5M
↓ 66.76%
Net Income
-13.4M
↓ 40.99%
Net Profit Margin
-107.27%
↓ 46.85%
FY19Y/Y Change
Total Assets
46.7M
-
Total Liabilities
251.2M
-
FY20Y/Y Change
Total Assets
92.0M
↑ 97.17%
Total Liabilities
313.9M
↑ 24.94%
FY21Y/Y Change
Total Assets
115.1M
↑ 25.04%
Total Liabilities
71.0M
↓ 77.38%
FY22Y/Y Change
Total Assets
68.9M
↓ 40.13%
Total Liabilities
51.7M
↓ 27.14%
Q4 FY21Q/Q Change
Total Assets
115.1M
↑ 41.76%
Total Liabilities
71.0M
↓ 78.39%
Q1 FY22Q/Q Change
Total Assets
100.5M
↓ 12.68%
Total Liabilities
65.8M
↓ 7.37%
Q2 FY22Q/Q Change
Total Assets
94.0M
↓ 6.51%
Total Liabilities
63.1M
↓ 4.03%
Q3 FY22Q/Q Change
Total Assets
83.8M
↓ 10.81%
Total Liabilities
62.3M
↓ 1.33%
Q4 FY22Q/Q Change
Total Assets
68.9M
↓ 17.78%
Total Liabilities
51.7M
↓ 16.94%
Q1 FY23Q/Q Change
Total Assets
85.2M
↑ 23.61%
Total Liabilities
51.1M
↓ 1.2%
FY19Y/Y Change
Operating Cash Flow
-19.8M
-
Investing Cash Flow
-223.0K
-
Financing Cash Flow
43.2M
-
FY20Y/Y Change
Operating Cash Flow
-12.2M
↓ 38.15%
Investing Cash Flow
-15.5M
↑ 6829.6%
Financing Cash Flow
18.1M
↓ 58.11%
FY21Y/Y Change
Operating Cash Flow
-22.4M
↑ 82.82%
Investing Cash Flow
-25.6M
↑ 65.56%
Financing Cash Flow
71.2M
↑ 293.94%
Q4 FY21Q/Q Change
Operating Cash Flow
-17.3M
↑ 237.18%
Investing Cash Flow
-24.7M
↑ 5967.81%
Financing Cash Flow
46.2M
↑ 124697.3%
Q1 FY22Q/Q Change
Operating Cash Flow
-7.6M
↓ 55.82%
Investing Cash Flow
-82.0K
↓ 99.67%
Financing Cash Flow
-5.0M
↓ 110.82%
Q2 FY22Q/Q Change
Operating Cash Flow
-5.5M
↓ 27.93%
Investing Cash Flow
-41.0K
↓ 50.0%
Financing Cash Flow
18.0K
↓ 100.36%
Q3 FY22Q/Q Change
Operating Cash Flow
-6.8M
↑ 23.8%
Investing Cash Flow
-2.0K
↓ 95.12%
Financing Cash Flow
13.0K
↓ 27.78%

Technicals Summary

Sell

Neutral

Buy

MINERVA SURGICAL, INC. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
MINERVA SURGICAL, INC.
MINERVA SURGICAL, INC.
-8.04%
23.99%
-90.38%
-97.44%
-97.44%
R1 RCM Inc
R1 RCM Inc
3.35%
94.67%
-25.2%
51.37%
101.76%
10X Genomics Inc
10X Genomics Inc
0.61%
50.7%
3.01%
-32.37%
-0.04%
Veeva Systems Inc.
Veeva Systems Inc.
-8.07%
-9.3%
-2.81%
-24.39%
118.28%
GE HEALTHCARE TECHNOLOGIES INC.
GE HEALTHCARE TECHNOLOGIES INC.
-2.58%
30.1%
30.1%
30.1%
30.1%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
MINERVA SURGICAL, INC.
MINERVA SURGICAL, INC.
NA
NA
NA
-0.37
-1.0
-0.27
0.0
0.19
R1 RCM Inc
R1 RCM Inc
128.18
NA
0.77
0.04
-0.06
0.04
0.0
6.5
10X Genomics Inc
10X Genomics Inc
NA
NA
NA
-1.42
-0.22
-0.11
0.0
6.91
Veeva Systems Inc.
Veeva Systems Inc.
54.75
54.75
1.27
4.18
0.15
0.07
0.0
23.48
GE HEALTHCARE TECHNOLOGIES INC.
GE HEALTHCARE TECHNOLOGIES INC.
21.41
21.41
NA
3.73
0.16
0.06
0.0
14.72
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
MINERVA SURGICAL, INC.
MINERVA SURGICAL, INC.
Buy
$44.6M
-97.44%
NA
-66.54%
R1 RCM Inc
R1 RCM Inc
Buy
$7.0B
101.76%
128.18
-4.41%
10X Genomics Inc
10X Genomics Inc
Buy
$6.0B
-0.04%
NA
-32.51%
Veeva Systems Inc.
Veeva Systems Inc.
Buy
$26.0B
118.28%
54.75
22.63%
GE HEALTHCARE TECHNOLOGIES INC.
GE HEALTHCARE TECHNOLOGIES INC.
Buy
$36.3B
30.1%
21.41
9.17%

Institutional Holdings

  • NEA Management Company, LLC

    5.65%
  • Vivo Capital, LLC

    1.25%
  • Versant Venture Management LLC

    0.95%
  • Awm Investment Company Inc

    0.94%
  • Bridgeway Capital Management, LLC

    0.07%
  • UBS Group AG

    0.02%

Corporate Announcements

  • MINERVA SURGICAL, INC. Earnings

    MINERVA SURGICAL, INC.’s price-to-earnings ratio stands at None

    Read More

Company Information

Organization
MINERVA SURGICAL, INC.
Employees
174
CEO
Mr. David M. Clapper
Industry
Healthcare

FAQs